Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Growth Plan

Add To Compare

previously known as Reliance Pharma Dir Gr until

NAV on May 29, 2020
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 2,851 cr
Turnover Ratio 34.67%
Expense Ratio 1.30%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: 3.55%
  • 1Y: 29.70%
  • 3M: 19.82%
  • 3Y: 17.51%
  • 6M: 23.24%
  • 5Y: 7.34%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since about 15 years) Kinjal Desai (Since about 2 years)
ISIN INF204K01I50
Fund Family Nippon India
P/E Ratio 29.27
P/B Ratio 3.60
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 9.47
Beta 0.85
R-Squared 95.28
Info Ratio 1.85
Tracking Err 5.74
Sortino -
Sharpe -
Std Dev 20.131
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

You will not receive any dividends. Your investments will get the largest benefit of compounding.

View Factsheet

-
Best Sector Healthcare Funds
NAME LATEST
NAV
RETURNS
1y    
FUND
ASSETS
Expense
RATIO
RISK
14.120 37.45% 526 cr 0.78% -
197.958 29.70% 2,851 cr 1.3% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India